Bayesian interpretation of p values in clinical trials.

Area of Science:

• Biostatistics
• Clinical Trials
• Evidence-Based Medicine

Background:

• Large sample sizes and high statistical power are generally considered superior for generating reliable clinical trial evidence.
• Accurate treatment effect estimates and reduced publication bias are typically associated with larger trials.

Purpose of the Study:

• To explain a counterintuitive statistical phenomenon where larger clinical trials with identical p-values may provide weaker evidence than smaller trials.
• To discuss the implications for interpreting and analyzing clinical trial data.

Main Methods:

• The study illustrates a statistical concept using hypothetical clinical trial scenarios.
• It focuses on the relationship between sample size, p-values, and the strength of evidence for treatment effectiveness.

Main Results:

• When two trials yield the same p-value, the larger trial may paradoxically offer less compelling evidence of a true treatment effect.
• This occurs because larger sample sizes can amplify the impact of small, unobserved effects, leading to statistically significant but potentially less meaningful results.

Conclusions:

• Statistical significance (p-value) alone is insufficient to gauge the strength of evidence; sample size plays a critical, often counterintuitive, role.
• Re-evaluation of how clinical trial results are interpreted and analyzed is necessary, considering the interplay between sample size and statistical significance.